Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02319005 · ClinicalTrials.gov registry record · Phase 3
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
A Phase 3 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 206
- Enrollment target
NCT02319005 is a Phase 3 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 206 participants.
The verdict
NCT02319005, a Phase 3 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 206 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and efficacy of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy. Dosing has been discontinued; patients are being followed-up for safety.
Interventions
- DRUG Sterile Normal Saline (0.9% NaCl)
- DRUG Revusiran (ALN-TTRSC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02319005
The ClinicalTrials.gov registry entry for NCT02319005 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sterile Normal Saline (0.9% NaCl) is the first listed.
NCT02319005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02319005 about?
NCT02319005 is a clinical study titled "ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)". The purpose of this study was to evaluate the safety and efficacy of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy. Dosing has been discontinued; patients are being followed-up for safety.
What is the current status of trial NCT02319005?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 2014-12. Estimated completion is 2017-03-30.
What interventions are being tested in trial NCT02319005?
The interventions under investigation include: Sterile Normal Saline (0.9% NaCl) (DRUG), Revusiran (ALN-TTRSC) (DRUG).
Who is sponsoring clinical trial NCT02319005?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.